GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » EV-to-FCF

SNY (Sanofi) EV-to-FCF : 33.49 (As of Oct. 31, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sanofi's Enterprise Value is $151,359 Mil. Sanofi's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $4,519 Mil. Therefore, Sanofi's EV-to-FCF for today is 33.49.

The historical rank and industry rank for Sanofi's EV-to-FCF or its related term are showing as below:

SNY' s EV-to-FCF Range Over the Past 10 Years
Min: 13   Med: 18.53   Max: 36.72
Current: 34

During the past 13 years, the highest EV-to-FCF of Sanofi was 36.72. The lowest was 13.00. And the median was 18.53.

SNY's EV-to-FCF is ranked worse than
60.45% of 531 companies
in the Drug Manufacturers industry
Industry Median: 24.81 vs SNY: 34.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-10-31), Sanofi's stock price is $52.88. Sanofi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $1.819. Therefore, Sanofi's PE Ratio (TTM) for today is 29.07.


Sanofi EV-to-FCF Historical Data

The historical data trend for Sanofi's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi EV-to-FCF Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.59 20.53 14.38 14.59 16.88

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 14.59 - 16.88 -

Competitive Comparison of Sanofi's EV-to-FCF

For the Drug Manufacturers - General subindustry, Sanofi's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sanofi's EV-to-FCF falls into.



Sanofi EV-to-FCF Calculation

Sanofi's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=151358.894/4519.063
=33.49

Sanofi's current Enterprise Value is $151,359 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $4,519 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi  (NAS:SNY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sanofi's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=52.88/1.819
=29.07

Sanofi's share price for today is $52.88.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $1.819.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sanofi EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sanofi's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.